Gene therapy versus protein-based therapy: A matter of pharmacokinetics

Drug Discovery Today

Volumn 6, Issue 15, 2001, Pages 769-770

  Post, Mark J ^a   Simons, Michael ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL SURFACE PROTEIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARAN SULFATE; LIGAND; VIRUS ANTIBODY;

ADENOVIRUS; ANGIOGENESIS; ATHEROSCLEROTIC PLAQUE; CELL SURFACE; CELLULAR IMMUNITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMORAL IMMUNITY; NONHUMAN; PROTEIN BINDING; SHORT SURVEY; SYSTEMIC CIRCULATION; TUMOR; VIRAL GENETICS; WOUND;

EID: 0035423553     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01904-3     Document Type: Short Survey

References (5)

1. Clinical efforts to modulate angiogenesis in the adult: Gene therapy versus conventional approaches
2. 125I-labeled basic fibroblast growth factor (bFGF) favor intramyocardial delivery
3. Binding properties, cell delivery, and gene transfer of adenoviral penton base displaying bacteriophage
4. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods
5. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains